Shares of Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) rose 4.2% during mid-day trading on Friday . The company traded as high as $6.15 and last traded at $6.15. Approximately 3,484 shares traded hands during trading, a decline of 75% from the average daily volume of 13,781 shares. The stock had previously closed at $5.90.
Innovent Biologics Trading Up 4.2 %
The stock’s 50-day moving average price is $5.02 and its 200-day moving average price is $5.03.
About Innovent Biologics
Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.
Recommended Stories
- Five stocks we like better than Innovent Biologics
- How is Compound Interest Calculated?
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- What is a Low P/E Ratio and What Does it Tell Investors?
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.